ACR® filed comments with the FDA in response to a request for comment regarding measuring and evaluating the performance of AI-enabled medical devices in real-world settings. This input will help inform FDA’s ongoing efforts to gather feedback on how to strengthen oversight of emerging AI technologies, including generative AI-enabled devices.
In its comments, ACR highlighted several ACR Data Science Institute® programs designed to support safe and effective implementation of AI in clinical settings, including:
ACR stressed the importance of local acceptance testing, governance and continuous monitoring. ACR also provided FDA with information on imaging AI performance metrics, evaluation methods and infrastructure, postmarket data sources and quality management, monitoring triggers and response protocols, and the importance of human-AI interaction and user experience.
For questions about ACR’s comments to the FDA, contact Michael Peters, ACR Senior Director, Government Affairs, or Lindsay Robbins, ACR Regulatory Policy Specialist.
MedPAC Backs Medicare Payment Increases for 2027
MedPAC urges Congress to raise payment rates for physicians and health professionals in 2027 and boost hospital safety‑net support by $1B.
Read moreACR Leaders Present 23 CPT Codes at RUC Meeting
ACR presented 23 CPT codes at the AMA RUC meeting, offering recommendations across key radiology procedures and preparing for the April 2026 cycle.
Read moreCongress Includes Increases to NIH in FY2026 Minibus
Proposed FY26 bill would give NIH $47.2B, keep ARPA‑H level, reject cuts, and preserve NIH structure and F&A support.
Read more